Join us at the 2nd Peptide-Based Therapeutics Summit, where we’ll unite the leading minds in peptide science to explore the ...

Learn more about the summit in the Event Guide here.

Modern medicine moves ever more to precision, personalised medicine, and precision dosing is critical in a world that ...

The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to ...

Since the start of the year, Ipsen has bolstered its oncology pipeline with two ADC alliances – with Foreseen Bio and Sutro ...

The Northern Ireland Protocol (NIP) that kept NI within the EU pharma regulatory system was widely derided for failing to resolve disparities between the EU and GB pharma regulatory environment, ...

Cost-effectiveness agency NICE has recommended NHS use of the therapy, called Kimmtrak (tebentafusp), for the treatment of ...

Thousands of men in the UK with advanced hormone-sensitive prostate cancer could soon be eligible for an oral therapy – Accord Healthcare's Orgovyx – that can be taken at home rather than ...

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-based drug for cancer.

The term "digital twins" has its origins in engineering and computer science, where it refers to a virtual replica of a physical object or system. Simply put, it is a sophisticated, dynamic, real ...

The way healthcare technology assessments (HTAs) are conducted in Europe is changing. In less than a year, all new advanced therapeutic products and oncology drugs will be subject to a mandatory ...